Autologous Stem Cell and Non-Stem Cell-Based Therapies Market is segmented By Type (Autologous Stem Cells, Autologous Non-Stem cells, Others), By Application (Cancer, Neurodegenerative Disorders, Cardiovascular Disease, Orthopedic Diseases, Others), By End-User (Hospitals, Ambulatory Surgical Centers, Research Facilities, Other), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031.
Autologous Stem Cell and Non-Stem Cell Based Therapies Market Overview
The Global Autologous Stem Cell and Non-Stem Cell-Based Therapies Market reached USD 6.8 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 18.4 billion by 2031. The Global Autologous Stem Cell and Non-Stem Cell-Based Therapies Market is expected to exhibit a CAGR of 13.7% from 2024 to 2031.
The growing number of chronic conditions, including neurodegenerative disorders, orthopedic injuries, and cardiovascular diseases, increasing demand for regenerative medicine, research advancements, and increase in market developments such as mergers, acquisitions, collaborations, product introductions, and approvals are among the fundamental elements expected to promote the global autologous stem cell and non-stem cell therapy based therapies market growth in the forecast period.
Autologous Stem Cell and Non-Stem Cell Based Therapies Market Scope
|
Metrics |
Details |
|
CAGR |
13.7% |
|
Size Available for Years |
2022-2031 |
|
Forecast Period |
2024-2031 |
|
Data Availability |
Value (US$) |
|
Segments Covered |
Type, Application, End-user |
|
Regions Covered |
North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
|
Fastest Growing Region |
Asia-Pacific |
|
Largest Region |
North America |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Type Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights. |
To know more Insights - Dowload Sample
Autologous Stem Cell and Non-Stem Cell Based Therapies Market Dynamics
Increasing Market Developments Drive the Growth of the Autologous Stem Cell and Non-Stem Cell Based Therapies Market
The increasing market developments in the autologous stem cell and non-stem cell-based therapies market are expected to boost the market growth in the forecast period. For instance, in May 2022, Sernova, a regenerative treatment corporation, and Evotec, a publicly listed drug discovery and designing corporation, formed a partnership for the creating a cell therapy to be utilized in the treatment of insulin-dependent diabetes employing induced pluripotent stem cells (iPSC)-based therapeutics.
Moreover, in October 2021, the U.S. FDA authorized the usage of the brexucabtagene autoleucel (Tecartus), a CAR-T therapy for patients with B-cell precursor ALL who have not reacted to previous therapy (refractory) or whose disease has returned after treatment.
The Research Funding is Expected To Present The Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market With Growth Opportunities
The increasing research funding is presenting the global market with prospective growth opportunities. For instance, in April 2023, the Board of the California Institute for Regenerative Medicine (CIRM) authorized funding about $89 million in projects from its Clinical and Translation programs at its April meeting.
About $39 million intends to fund four assignments in the agency’s clinical program, which quickens the aid and delivers grants for suitable stem cell and gene therapy-based projects via any stage of clinical trial activity.
The High Cost Of Autologous Cell Therapy is Estimated to Hamper the Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market During The Forecast Period
The high cost of autologous cell therapy is hampering the growth of global autologous stem cell and non-stem cell-based therapies in the forecast period. For instance, CAR T-cell therapy expense is estimated to be between US$500,000 and US$1,000,000.
Autologous Stem Cell and Non-Stem Cell Based Therapies Market Segment Analysis
The Global Autologous Stem Cell and Non-Stem Cell-Based Therapies Market is segmented based on type, application, end-user, and region.
The Cancer Application is Estimated to Dominate the Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market
Owing to the increasing cancer cases worldwide, the cancer application of autologous stem cell and non-stem cell-based therapies is estimated to dominate the global market holding around 39.7% of the worldwide market.
For instance, according to the WHO, cancer is a top reason of death globally, accounting for almost 10 million deaths in 2020. The highly typical new cancer cases in 2020 were breast cancer accounting for 2.26 million cases, lung cancer accounting for 2.21 million cases, colon and rectum making up for 1.93 million cases, and prostate cancer accounting for over 1.41 million cases.
Source: DataM Intelligence Analysis (2024)
Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market Geographical Penetration
North America is Estimated to hold Approximately 41.6% of the Market Share by 2030, Owing to the Increasing Cases of Chronic Conditions.
Due to the increasing chronic disorder cases in this region, North America is estimated to hold around 41.6% of the total Global Autologous Stem Cell and Non-Stem Cell-Based Therapies Market share throughout the forecast period.
For instance, the National Cancer Institute, in January 2022, estimated that there were over 18.1 million cancer survivors in the United States, representing around 5.4% of the population. Moreover, according to the American Cancer Society, in 2022, over 1,918,030 new cancer cases and about 609,360 cancer deaths were anticipated to transpire in the United States, including roughly 350 deaths each day from lung cancer, the top reason for cancer death.
Source: DataM Intelligence Analysis (2024)
Autologous Stem Cell and Non-Stem Cell Based Therapies Companies
The major global players in the autologous stem cell and non-stem cell-based therapies market include Novartis AG, BrainStorm Cell Limited, Caladrius, Cytori Therapeutics Inc., Gilead Sciences Inc., Regeneus Ltd, U.S. Stem Cell, Vericel Corporation, MEDIPOST, Castle Creek Biosciences, Inc., among others.
COVID-19 Impact on Autologous Stem Cell and Non-Stem Cell Based Therapies Market
Russia-Ukraine Conflict Analysis
The Russia-Ukraine brawl is considered to have minimal impact on the Global Autologous Stem Cell and Non-Stem Cell-Based Therapies Market because of the low prevalence and dearth of critical market players in this region. Yet, persisting to countenance raids from Russian troops, Ukrainian infirmaries are pushed by increasing numerals of deaths and specified medical aids.
There are deficiencies across all kinds of drugs. Again, the consequence of the import and export of basic materials is predicted to have a small influence on the growth of global autologous stem cell and non-stem cell-based therapies in the forecast period.
Key Developments
- In June 2022 cell therapy developer Tessa Therapeutics disclosed a $126M Series A round of grant to invest in continued clinical development of two additional kinds of cancer therapies. TT11 is the Singapore-based corporation’s autologous cell therapy, which is produced from a patient’s T cells. That cell therapy nominee targets the cancer protein CD30 and is being prepared to start a pivotal Phase 2 test later this year.
- In April 2022, Metcela, a clinical-stage biotech startup completed the acquisition of Japan Regenerative Medicine Co. Ltd to design cardiac stem cell-based therapy. Via the investment, Metcela is expected to add an autologous cell development for a pediatric congenital heart condition to its pipeline and greatly amplify its clinical development infrastructure for regenerative medicine developments.
- In December 2021, Novartis introduced its T-Charge, the corporation’s next-generation CAR-T platform that intends to function as the foundation for diverse new investigational CAR-T cell therapies in the Novartis pipeline.
Why Purchase the Report?
- To visualize the Global Autologous Stem Cell and Non-Stem Cell-Based Therapies Market segmentation based on type, application, end-user, and region, as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of autologous stem cell and non-stem cell-based therapies market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Type mapping available in Excel consisting of key types of all the major players.
The Global Autologous Stem Cell And Non-Stem Cell-Based Therapies Market Report Would Provide Approximately 53 Tables, 54 Figures And 195 Pages.
